Okay, I'm exaggerating but an overall gain of 6%
when the broader indexes are up 14% for the year isn't exactly a shot in the
arm.
For much of 2006, the health care sector,
particularly the biopharmaceutical sector, found itself fighting myriad
problems: anemic pipelines, widespread patent expirations; higher costs, and a
slew of legal and regulatory threats that saw no shortage of industry lawyers
in the courtrooms and in front of Congressional panels for much of the year.
Not helping the industry was the election of a Democratic Congress, which
triggered a four point drop in the American Stock Exchange Biotech Index in the
days after the November election.
But that was then and this now.
With the stock market cratering last Tuesday, a
recent series of iffy economic reports, and seemingly contrasting views on the
direction of the U.S. economy between the current and former Federal Reserve
Chairmen, health care looks like a strong defensive play in 2007. Analysts
project that the S&P Healthcare index will post an earnings increase
of 11% in 2007, compared with 5% profit growth for the S&P 500.
That, among other factors, could put a stake in
a health care mutual fund or exchange-traded fund (ETF) in play – a good
defensive stance when investors are taking a hands-off approach to more
aggressive sectors.
Healthy Sector
There's more to the health care sector than just
bad economic news and a spat between Ben Bernanke and Alan Greenspan. Sure,
with U.S. economic growth faltering a bit, a defensive sector like
health care should attract more attention. There is also plenty of good news
coming out of the sector in 2007, most notably:
- Strong valuations
- Tighter cost controls
- A slate of impressive new drug development
pipelines
- Solid balance
sheets
A host of sector
analysts see the same scenario I do.
Says Global
Insight, the Boston-based analytical group: "Among the 10 sectors that
comprise the U.S. stock market, the healthcare sector currently has the
best attributes for an overweight position, from both the fundamental and risk
perspectives. This is due to the robust prospects for strong growth in earnings
and free cash flow that result from positive demographics, new technology,
faster sales, and positive pricing power."
Much of the bullish
attention on the sector is honing in on biotech, where the historically
volatile industry seems to be calming down and shaping up in '07. "We see
impressive pipelines and we've seen an increase in biotech's willingness to
charge and receive premium pricing," says Eric Schmidt, a managing
director at Cowen who is bullish on health care this year.
A good, safe fund
like the Vanguard Health Care Fund fits well in this increasingly rosy scenario.
Fund manager Ed Owens is a veteran, steady hand at the helm – he's been with
the fund since 1984.
The guy knows the
landscape. Take 2006 -- in a year when health care stocks underperformed
relative to other key S&P Indexes, Owens looked overseas to the fund's
European and Japanese pharma holdings, such as Roche and Takeda Chemical, which
helped pump up returns and help the fund outperform last year. (The fund
returned 10.87% last year, well ahead of its benchmark S&P Healthcare
index).
Adaptability is
Owens' calling card – for example, the fund averages about 30% of its holdings
from overseas companies – and it has paid off handsomely over the years for
fund investors.
It all adds up to a
major long-term buying opportunity in 2007. The key ingredients are all there –
an economy expected to slow in 2007, a record-number of Baby Boomers
hitting 60, and a market move away from aggressive stocks and into defensive
ones.
Consequently, I see an unstoppable trend with
health care stocks in 2007.